Nimesulide Pensa

Nimesulide, the active ingredient in Nimesulide Pensa, is a NSAID presented as an oral tablet for oral use. It is employed to relieve pain, reduce inflammation, lower fever, and manage osteoarthritis and dysmenorrhea in adult patients. It is indicated for short‑term therapy and is available in the European market under strict manufacturing controls.

GNH USA supplies Nimesulide Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Nimesulide acts as an analgesic and anti‑inflammatory agent targeting prostaglandin‑mediated pathways.

Pain: alleviates mild to moderate acute or chronic pain associated with musculoskeletal conditions. Inflammation: reduces inflammatory swelling in conditions such as sprains and soft‑tissue injuries. Fever: lowers elevated body temperature in febrile states. Osteoarthritis: improves joint pain and functional mobility in osteoarthritis patients. Dysmenorrhea: eases menstrual pain and associated discomfort.

Nimesulide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, abdominal pain. - Headache: mild to moderate intensity. - Dizziness: transient vertigo or light‑headedness. - Skin rash: mild erythema or itching. - Elevated liver enzymes: transient increase in transaminases. - Diarrhoea: loose stools without blood.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury or jaundice. - Stevens‑Johnson syndrome: serious skin and mucosal reactions. - Blood dyscrasias: agranulocytosis or thrombocytopenia. - Renal impairment: acute kidney injury. - Anaphylaxis: life‑threatening allergic reaction. - Severe cutaneous adverse reactions: toxic epidermal necrolysis.

Before prescribing Nimesulide, clinicians should evaluate several safety considerations to minimize risk.

Assess liver function: obtain baseline hepatic enzymes and monitor periodically during therapy. Avoid prolonged use: limit treatment duration to the shortest effective period to reduce toxicity risk. Review concomitant NSAIDs: do not combine with other non‑steroidal anti‑inflammatory drugs to prevent additive gastrointestinal and renal effects. Consider cardiovascular risk: use cautiously in patients with hypertension or known cardiovascular disease. Pregnancy and lactation: avoid use during pregnancy and breastfeeding due to insufficient safety data. Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and direct sunlight.

Nimesulide can interact with several medicines, requiring careful management of co‑administered drugs.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: heightened gastrointestinal toxicity. - Lithium: elevated lithium serum levels. - Methotrexate: reduced clearance leading to toxicity. - Cyclosporine: increased nephrotoxicity.

Moderate Interactions (Monitor Closely): - Antihypertensives (ACE inhibitors, ARBs): possible reduction in antihypertensive effect. - Diuretics: risk of renal function decline. - SSRIs: modest increase in bleeding tendency. - Corticosteroids: additive risk of gastrointestinal ulceration. - Oral hypoglycemics: potential alteration of blood glucose control.